| Inclusion Criteria: | 1) Patients must have metastatic RCC, have a primary lesion in place, are being considered for presurgical systemic therapy.
2) Subjects must have an ECOG performance score of 0-2.
3) Subjects must have adequate renal function as defined by serum creatinine </=1.5 mg/dL or a calculated creatinine clearance of 60 ml/min.
4) Eligible subjects must have a primary tumor in place.
5) Patients must have at least one lesion located in the kidney. The index lesion should demonstrate visible contrast enhancement on the most recent CT or MRI scan (i.e. not cysts).
6) When there are multiple lesions, one lesion should be chosen as the index lesion. Other tumors in the scan volume should be considered of lesser importance.
7) The index lesion should be the most enhancing tumor which meets all other criteria.
8) The imaging acquisition volume should be centered on the index lesion.
9) When possible, the index lesion should be fully encompassed by the imaging acquisition volume.
10) Index lesions should be chosen to avoid motion and beam hardening artifact, particularly from vascular structures, extending into the tumor.
11) The volume of interest defined in the baseline study should be used for subsequent studies.
12) The Principal Investigator or co-Principal Investigators will have discretion to select as index lesion, the lesion which most closely match the selection criteria. |